title: Comparison of early and late treatment with a recombinant endotoxin neutralizing protein in a rat model of Escherichia coli sepsis.
abstract: OBJECTIVE
  To test the efficacy of a recombinant endotoxin neutralizing protein as compared with saline in rats with Escherichia coli sepsis.
  
  
  METHODS
  Prospective, controlled animal trial.
  
  
  METHODS
  Hospital animal research laboratory.
  
  
  METHODS
  Male Wistar rats challenged with intraperitoneal E. coli, O18ac K1, and treated 1 hr later with ceftriaxone and gentamicin.
  
  
  METHODS
  Recombinant endotoxin neutralizing protein, 50 mg/kg, was administered to rats 1, 2, or 3 hrs after E. coli challenge; saline was administered to control animals.
  
  
  RESULTS
  Quantitative bacteremia, 1 hr after challenge and before antibiotic administration, was not significantly different between treatment groups (range geometric mean 451 to 621 colony-forming units [cfu]/mL). The endotoxin concentration, measured immediately before recombinant endotoxin neutralizing protein administration, was significantly higher in animals sampled and treated at 2 hrs (geometric mean 260 EU/mL; 95% confidence interval 140 to 480 EU/mL), or 3 hrs (geometric mean 697 EU/mL; 95% confidence interval 307 to 1585 EU/mL) after E. coli challenge, compared with animals sampled and treated at 1 hr (geometric mean 17 EU/mL; 95% confidence interval 7 to 69 EU/ mL). Survival rate was significantly greater in rats treated with recombinant endotoxin neutralizing protein at 1 hr (23/27; p < .001) or 2 hrs (8/30; p < .01) after E. coli challenge than in controls (1/32).
  
  
  CONCLUSIONS
  Administration of recombinant endotoxin neutralizing protein delayed up to 2 hrs after challenge with E. coli improves survival in antibiotic-treated rats with Gram-negative sepsis.
authors.affiliation: Department of Medicine, Children's Hospital, Harvard Medical School, Boston, MA 02115, USA.
authors.forename: D L
authors.initials: DL
authors.lastname: Weiner
authors.forename: N
authors.initials: N
authors.lastname: Kuppermann
authors.forename: R A
authors.initials: RA
authors.lastname: Saladino
authors.forename: C M
authors.initials: CM
authors.lastname: Thompson
authors.forename: T J
authors.initials: TJ
authors.lastname: Novitsky
authors.forename: G R
authors.initials: GR
authors.lastname: Siber
authors.forename: G R
authors.initials: GR
authors.lastname: Fleisher
mesh_terms: D000818:Animals; D000890:Anti-Infective Agents / Q000097:blood / Q000627:therapeutic use*; D023181:Antimicrobial Cationic Peptides; D060829:Arthropod Proteins; D004195:Disease Models, Animal; D004731:Endotoxins / Q000097:blood; D004927:Escherichia coli Infections / Q000188:drug therapy*; D007447:Invertebrate Hormones / Q000097:blood / Q000627:therapeutic use*; D008297:Male; D011446:Prospective Studies; D011897:Random Allocation; D051381:Rats; D017208:Rats, Wistar; D018805:Sepsis / Q000188:drug therapy*; D015996:Survival Rate
chemical_list: D000890:Anti-Infective Agents; D023181:Antimicrobial Cationic Peptides; D060829:Arthropod Proteins; D004731:Endotoxins; D007447:Invertebrate Hormones; C034705:antilipopolysaccharide factor (Limulus)